Skip to main content

Peer Review reports

From: HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

Original Submission
26 Mar 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
9 May 2022 Reviewed Reviewer Report - Vera Rebmann
18 May 2022 Reviewed Reviewer Report - Dimitri S. Monos
26 May 2022 Author responded Author comments - Junying Xu
Resubmission - Version 3
26 May 2022 Submitted Manuscript version 3
13 Jun 2022 Author responded Author comments - Junying Xu
Resubmission - Version 4
13 Jun 2022 Submitted Manuscript version 4
15 Jun 2022 Author responded Author comments - Junying Xu
Resubmission - Version 5
15 Jun 2022 Submitted Manuscript version 5
Publishing
27 Jun 2022 Editorially accepted
6 Jul 2022 Article published 10.1186/s12885-022-09840-6

You can find further information about peer review here.

Back to article page